CASRAI Dictionary

Tag: material transfer agreement policy

  • Types of Material Transfer Agreement Guide: One-Way, Two-Way and Commercial-Use MTAs

    Types of material transfer agreement fall into two overlapping categories: direction of transfer (one-way versus two-way) and nature of the parties (academic/non-profit versus commercial-use). Choosing the wrong category adds weeks of unnecessary negotiation to a simple exchange, or leaves an institution exposed on intellectual property and liability in a complex one. A material transfer agreement (MTA) is a contract that governs the transfer of tangible research materials — cell lines, plasmids, reagents, antibodies, animal models, or genetic constructs — between a provider and a recipient, setting terms for permitted use, publication, and downstream rights.

    What is a material transfer agreement, and why does type matter?

    A material transfer agreement is the legal instrument accompanying the physical movement of a research material between organisations. It records who owns the original material, what the recipient may do with it, who owns derivatives the recipient creates, and what happens if the material leads to a publication or invention.

    Institutions do not use one template for every transfer. The right MTA type depends on two independent variables: direction of the exchange, and the nature of the parties — non-profit or commercial. Mismatching the template to either variable is a common cause of avoidable negotiation delay.

    One-way vs two-way MTAs: what is the difference?

    A one-way MTA covers a single direction of transfer: one provider sends material to one recipient, who accepts the provider’s terms. Most institutional MTAs are one-way and are further split into two sub-types depending on which side of the transaction the institution sits on.

    • Incoming MTA — the institution is the recipient. The priority is understanding and accepting the provider’s restrictions: permitted research use, any prohibition on commercial use, and publication or embargo terms.
    • Outgoing MTA — the institution is the provider. The priority shifts to protecting the institution’s own intellectual property, limiting liability for the material’s performance, and controlling further distribution by the recipient.

    A two-way (or reciprocal) MTA is used when both parties send materials to each other, typically in an active collaboration where each lab holds a resource the other needs. Rather than negotiate two separate one-way agreements, the parties combine both transfers into a single reciprocal agreement with symmetric obligations. This is administratively efficient but requires both sides to specify their respective materials and restrictions with equal precision — asymmetric two-way MTAs are a frequent source of later disputes over derivative rights.

    MTA type Direction Typical parties Primary administrative focus
    Incoming (one-way) Provider → institution Academic-to-academic or vendor-to-academic Compliance with provider’s use and publication restrictions
    Outgoing (one-way) Institution → external recipient Academic-to-academic or academic-to-industry IP retention, liability limitation, distribution control
    Two-way / reciprocal Bidirectional Collaborating academic labs Symmetric terms for both transferred materials
    Academic/non-profit Either direction Non-profit-to-non-profit Non-commercial research use only; minimal negotiation
    Commercial-use Either direction At least one for-profit party IP ownership, licensing options, publication delay, indemnification

    Academic/non-profit vs commercial-use MTAs: how do the terms differ?

    The second axis of classification is the nature of the parties, and it changes negotiation complexity more than direction does. A biological material transfer agreement between two non-profit universities is usually a light-touch document; the same transfer involving a commercial partner routinely takes months longer to close.

    Academic and non-profit MTAs exist to facilitate open scientific exchange. The US National Institutes of Health (NIH) has stated that unique research resources arising from NIH-funded work should be shared on terms no more restrictive than its own model agreements, because repeated case-by-case negotiation between non-profits delays the point at which a research tool reaches the laboratory bench. These agreements typically restrict use to non-commercial research, require no royalty, and rarely need individual negotiation once a standard template is adopted.

    Commercial-use MTAs — where a for-profit company is provider, recipient, or both — carry additional, negotiated terms that a non-profit template does not anticipate:

    • Intellectual property rights over inventions made using the transferred material, including whether the provider retains an option to license.
    • Publication rights, including any pre-publication review period the commercial party can invoke to protect confidential information.
    • Scope of permitted use, distinguishing internal research from development toward a commercial product, which may trigger the need for a separate licence agreement.
    • Indemnification and liability allocation, which non-profit-to-non-profit templates typically waive or cap at a nominal level.

    A material transfer agreement policy should specify, in advance, which of these terms are non-negotiable defaults and which require case-by-case legal review — allowing routine academic MTAs to clear in days, reserving negotiation capacity for the commercial-use cases where it is genuinely needed.

    Which standard templates exist, and how do you choose the right one?

    Four template families cover the great majority of transfers, and matching a transfer to the correct family is the fastest route to a signed agreement.

    • NIH Simple Letter Agreement (SLA), published in 1995 by the NIH, is a one-page model for low-risk, non-commercial transfers of routine research materials between non-profit institutions.
    • Uniform Biological Material Transfer Agreement (UBMTA), also introduced in 1995, is the master agreement signed once by an institution; individual transfers under it use a short “Implementing Letter” rather than a fresh negotiation, and it is the standard route for a two-way material transfer agreement between two UBMTA-signatory non-profits.
    • AUTM Model MTAs extend the UBMTA framework to materials — and non-US institutions — outside the UBMTA’s original definition of biological material; a 2011 AUTM member survey found low adoption of standard templates was itself a major cause of unnecessary delay, which the toolkit’s decision tree was built to address.
    • FAO Standard Material Transfer Agreement (SMTA), adopted by the Governing Body of the International Treaty on Plant Genetic Resources for Food and Agriculture in 2006, is a distinct global instrument governing plant genetic resources held in the Treaty’s Multilateral System, with mandatory benefit-sharing terms that have no equivalent in the UBMTA or NIH templates.

    To choose: start by identifying direction (one-way or two-way) and party type (non-profit or commercial). If both parties are non-profit and the material is biological, default to the UBMTA or SLA. If a commercial party is involved, route the transfer to legal review rather than a standard template. If the material is a plant genetic resource in the Multilateral System, the FAO SMTA applies regardless of the parties’ institutional type — a distinction general MTA guidance frequently omits.

    Frequently asked questions

    What is a material transfer agreement?

    A material transfer agreement is a contract governing the transfer of tangible research materials — such as cell lines, plasmids, reagents, or animal models — between a provider and a recipient. It sets terms for permitted use, ownership of derivatives, publication rights, and liability, and is negotiated before the physical material is shipped.

    What is the difference between an MTA and an NDA?

    An NDA (non-disclosure agreement) protects confidential information exchanged between parties, while an MTA governs the physical transfer and permitted use of a tangible material. The two are often signed together — an NDA may protect data about the material, while the MTA governs the material itself — but neither substitutes for the other.

    What is the standard material transfer agreement?

    The Standard Material Transfer Agreement (SMTA) is the FAO instrument used specifically for plant genetic resources held under the International Treaty on Plant Genetic Resources for Food and Agriculture’s Multilateral System. It is distinct from the UBMTA used for general biological materials and includes mandatory benefit-sharing obligations tied to the Treaty.

    Implications and outlook for research administrators

    Institutions that map every incoming request against this taxonomy before drafting — direction first, party type second, then template — process the majority of routine biological material transfer agreement requests without individual legal review. That triage is what standard templates like the UBMTA and NIH SLA were designed to enable, and what a written material transfer agreement policy should formalise as institutional default practice.

    The remaining minority — commercial-use transfers, cross-border plant genetic material, and asymmetric two-way exchanges — is where administrative time should concentrate, since these are the categories where the wrong template creates the greatest downstream IP and compliance risk. As collaborations increasingly span academic, industry, and international-treaty jurisdictions at once, classifying a transfer correctly at intake, rather than after a dispute arises, remains the most effective control a research administration office can apply.

  • When Is a Material Transfer Agreement Required? A Decision Framework

    A material transfer agreement is required whenever tangible, non-public research materials — cell lines, plasmids, antibodies, reagents, transgenic organisms, or associated data — move between two separate legal entities and the provider wants to retain ownership, control future use, or protect intellectual property. If the material is freely purchasable on the open market, or if it never leaves the same legal entity, no material transfer agreement is needed. Between those two extremes sits a middle case — a simple loan or implementing letter — that many institutions handle incorrectly, which is the gap this framework closes.

    A material transfer agreement (MTA) is a legally binding contract that sets out the terms under which tangible research materials are supplied by one organisation (the provider) and used by another (the recipient), covering ownership, permitted use, publication rights, liability, and the treatment of any resulting inventions.

    Contents

    What is a material transfer agreement?

    A material transfer agreement is the contract vehicle research institutions use to move physical research materials — rather than data or funding — between organisations while preserving each party’s rights. It typically fixes four things: who owns the original material, what the recipient may do with it, who owns anything invented using it, and whether results can be published without restriction.

    MTAs sit alongside, but are distinct from, confidentiality agreements and sponsored-research agreements. A confidentiality agreement protects information; an MTA protects a physical or biological thing. Where data accompanies the material — sequencing reads, patient metadata, assay results — many institutions issue a linked Data Transfer Agreement (DTA) rather than folding data terms into the MTA itself.

    When is a material transfer agreement required?

    An MTA is required whenever three conditions are all true: the item is tangible (not purely information), it is not freely available for anyone to buy, and the provider wants to attach conditions to its use. Absent any one of those three, a lighter mechanism — or nothing — usually suffices.

    The general triggers

    Institutions typically require a full MTA for: proprietary cell lines and plasmids; genetically modified organisms; patient- or human-derived samples; antibodies or reagents developed in-house; software tied to physical hardware; and any material being sent to, or received from, a for-profit company. The University of Manchester’s contracts team states plainly that an MTA is required for the transfer of materials and/or data between the University and a third party, but explicitly carves out one exception: if the materials are available to purchase on the open market, an MTA will not be required, because that transaction is simply a purchase handled through procurement.

    Special categories that raise the bar

    Three categories demand extra scrutiny before any material moves, regardless of how “routine” the transfer feels:

    • Human-derived material — samples covered by the UK Human Tissue Act 2004 require Human Tissue Authority (HTA) licensing checks and research ethics approval before any transfer agreement is signed.
    • Genetic resources sourced internationally — transfers of genetic material obtained from a provider country after the Nagoya Protocol entered into force in 2014 trigger access-and-benefit-sharing (ABS) obligations under the Convention on Biological Diversity, independent of whatever the MTA itself says.
    • Plant genetic resources for food and agriculture — material listed under the Multilateral System of the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA, in force since 2004) must move under the FAO’s Standard Material Transfer Agreement (SMTA), a fixed-form contract that cannot be substituted with an institution’s own template.

    Materials crossing borders may also need export-control clearance where dual-use or sensitive technology is involved, and third-party funding terms must be checked for conflicts before an MTA is countersigned — a funder’s data-sharing mandate can directly contradict a provider’s proposed use restrictions.

    The decision framework: full MTA, simple letter, or no agreement

    Most guidance treats “do I need an MTA” as binary. In practice, research offices work with three tiers, and choosing the wrong one either creates unnecessary friction or leaves an institution legally exposed.

    Scenario Mechanism Why
    Unmodified biological material moving between two non-profit institutions that are both signatories to a master agreement Simple implementing/loan letter Terms are pre-agreed once; each transfer just references the master deal, e.g. under the NIH-developed Uniform Biological Material Transfer Agreement (UBMTA)
    Proprietary, modified, human-derived, or export-controlled material; any transfer involving a for-profit party Full negotiated MTA Ownership, publication rights, IP on improvements, and liability all need bespoke terms
    Material freely available for purchase on the open market, or moving within the same legal entity No agreement (procurement or internal process only) There is no proprietary right or cross-entity risk to allocate
    Plant genetic resources under the ITPGRFA Multilateral System FAO Standard Material Transfer Agreement (SMTA) A treaty-mandated fixed form; institutions cannot substitute their own template

    The middle tier is the one most frequently mishandled. Under the UBMTA — a master agreement developed under the auspices of the US National Institutes of Health in 1995 — signatory institutions exchange unmodified biological materials using a one-page implementing letter instead of renegotiating terms each time. But even under UBMTA cover, a full bespoke MTA is still required the moment the material is human-derived, genetically modified, or hazardous, or if either party is not a signatory.

    Practically, ask four questions in order:

    1. Is the material purchasable off the shelf? If yes, stop — use procurement, not an MTA.
    2. Does a signed master agreement (e.g. UBMTA) already cover both institutions and this exact material type unmodified? If yes, a loan/implementing letter is sufficient.
    3. Is either party for-profit, or is the material modified, human-derived, genetically modified, or export-controlled? If yes, a full negotiated MTA is required.
    4. Is the material a plant genetic resource under the ITPGRFA Multilateral System? If yes, the FAO SMTA applies and overrides institutional templates.

    Answer-first Q&A

    Do I need an MTA?

    You need an MTA if you are sending or receiving tangible, non-public research material — biological samples, reagents, cell lines, or similar — to or from a different legal entity. If the material is commercially purchasable or stays within your own institution, no agreement is required; check with your contracts office before assuming either way.

    What is a material transfer agreement?

    A material transfer agreement is a contract between a provider and a recipient organisation that documents the material being transferred and the terms governing its ownership, permitted use, publication, and any resulting inventions. It protects both parties’ intellectual property and clarifies liability before materials change hands.

    What is the standard material transfer agreement (SMTA)?

    The Standard Material Transfer Agreement is the fixed-form contract required under the FAO’s International Treaty on Plant Genetic Resources for Food and Agriculture. It governs transfers of listed plant genetic resources within the treaty’s Multilateral System and cannot be replaced by an institution’s own MTA template.

    Why do institutions require an MTA?

    Institutions require an MTA to protect ownership of proprietary materials, define permitted research use, and settle publication and inventorship rights in advance. Without one, disputes over who owns follow-on discoveries or who may publish first become far harder to resolve after the fact.

    Implications for research administrators

    Getting the tier wrong has real cost on both sides. Forcing every transfer through a full negotiated MTA slows down routine science and burdens contracts teams already stretched thin. Skipping an agreement where one is legally required — particularly for human-derived or export-controlled material — exposes the institution to compliance action and jeopardises the researcher’s ability to publish or patent.

    A working checklist for any incoming or outgoing transfer should confirm: the material’s category (unmodified biological, modified, human-derived, genetic resource, software, data); whether either party is for-profit; whether a signatory master agreement already applies; whether human tissue, Nagoya Protocol, or export-control obligations attach; and who at the institution holds authority to sign, since most universities restrict MTA signature to a small number of authorised contracts officers rather than the individual researcher.

    As research materials increasingly cross borders and sectors — biobanks, industry-academic partnerships, international consortia — the three-tier framework above gives administrators a faster, defensible route to the right mechanism, rather than defaulting every transfer to the slowest, most conservative option. For related definitions and terminology used across research administration, see the CASRAI Dictionary and the broader research administration resource hub.